The appointment of Lanesha Minnix as general counsel highlights how governance, regulation and public affairs are increasingly central to strategy at global medical technology companies.
BD (Becton, Dickinson and Company) has named Lanesha Minnix as executive vice president and general counsel, effective March 16, placing an experienced legal executive at the center of its leadership team. She will oversee the company’s Law Group and Public Affairs and join the executive leadership team of the Franklin Lakes, New Jersey–based medical technology firm.
The move comes at a time when healthcare companies operate in an environment shaped by regulatory scrutiny, supply chain pressures and rapid technological change. For a global manufacturer of medical devices and diagnostics that delivers billions of products annually, legal and public affairs functions are deeply intertwined with product innovation, compliance and market access. The general counsel’s office is no longer limited to risk mitigation but plays a role in enabling growth while managing policy complexity.
Minnix most recently served as executive vice president and chief legal officer at Walgreens Boots Alliance, where she led legal, corporate affairs, risk and security functions. She was involved in the company’s $24 billion take-private transaction, one of the largest in the health care and retail sectors. Earlier roles at Ecolab and Flowserve included building global compliance programs and strengthening governance frameworks, experience that may prove relevant as BD navigates evolving regulatory standards and international markets.
Medical technology firms face increasing expectations around product safety, data privacy, global trade compliance and environmental standards. At the same time, they are under pressure to accelerate innovation and expand access to care. The intersection of these demands requires legal leadership that can coordinate across business units while maintaining clear accountability to regulators and stakeholders.
By appointing Minnix to a dual role that includes public affairs oversight, BD appears to be aligning legal strategy with external engagement. In a healthcare system where policy shifts can influence reimbursement, product approvals and supply dynamics, the ability to anticipate and respond to regulatory change is a strategic capability. The appointment signals that governance and operational discipline remain central to BD’s long-term positioning in a complex global market.
